Please assess the completion status of the following clinical trial:

Trial Title: Fondaparinux for the Treatment of Heparin-Induced Thrombocytopenia (HIT)

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* high risk for HIT based on Four Ts score of 6 or more~Exclusion Criteria:~* pulmonary emboli at the time of enrollment~* arterial thrombosis at the time of enrollment~* limb threatening phlegmasia cerulea dolens at the time of enrollment~* Calculated Creatinin Clearance less than 50 ml/hr~* platelet count less than 50~* Weight less than 50 kg~* pregnancy~* allergy to fondaparinux~* bacterial endocarditis~* history of neuraxial anesthesia and post-operative indwelling epidural catheter~* active major bleeding (hemodynamically significant or requiring transfusions)~* inability to give informed consent

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Fondaparinux (Type: EXPERIMENTAL): daily subcutaneous injection of fondaparinux (7.5-10 mg)

Based on this trial design, predict the completion outcome and termination type (if applicable).